Postural orthostatic tachycardia syndrome (POTS) is a disorder of the autonomic nervous system. It causes a heart rate increase of at least 30 beats per minute upon standing. Symptoms include dizziness, brain fog, fatigue, and palpitations. For many patients, these symptoms significantly limit daily activity. The good news is that clinical awareness is growing rapidly, and more patients are getting accurate diagnoses than ever before. A 2025 Australian registry study by Seeley et al. tracked 500 patients and found they consulted an average of 5.2 physicians before diagnosis, with a mean delay of 6.7 years. More than 25 percent waited over a decade for an answer. Earlier data from Shaw et al. (2019) placed the average physician count at seven across 4,835 patients. These numbers show that diagnosis delays remain a challenge, and they highlight exactly why subtype-specific evaluation is so valuable. The latest treatment approaches make clear that identifying the precise biological subtype is the most important step toward lasting relief. Dysautonomia International and the NIH National Institute of Neurological Disorders and Stroke both offer foundational resources for patients starting this journey.
Pathophysiology: The Three Primary Subtypes
Most patients first receive a standard protocol: increased salt, more fluids, compression garments, and possibly a beta-blocker. This approach helps some patients but leaves many others without adequate relief. The reason is straightforward. POTS is not a single disease. It is a syndrome with three recognized primary subtypes, each driven by a different physiological mechanism. Clinicians who know which subtype they are treating can target the root cause directly, rather than applying a one-size-fits-all approach. The 2015 Heart Rhythm Society expert consensus statement and Raj et al. (CMAJ, 2022) both describe these three subtypes and provide the framework clinicians use today. The Cleveland Clinic POTS overview also summarizes the subtype framework for patients and families.
Dr. Marc Ellis, Founder of Georgia Chiropractic Neurology Center in Marietta, Georgia, explains the diagnostic challenge this way:
“Standard autonomic testing usually stops at a tilt table, and a tilt table only tells you that the heart rate is rising on standing. It does not tell you why. The ‘why’ is whether the patient has a peripheral denervation problem in the legs, a hyperadrenergic surge, a hypovolemic baseline, or a brainstem regulation failure. Each of those scenarios responds to a different treatment. When the workup never goes beyond confirming POTS exists, the patient gets generic care. What we add is a network-level neurological exam: vestibulo-ocular reflex, oculomotor control, pupillary dynamics, posturography, and HRV at rest and under load. That is what separates ‘you have POTS’ from ‘we know which POTS you have.’”
— Dr. Marc Ellis, DC, MS, DACNB, FACFN, FABBIR, Founder, Georgia Chiropractic Neurology Center
1. Neuropathic Subtype
In the neuropathic presentation, small autonomic nerves in the lower extremities fail to signal blood vessels to constrict upon standing. Blood pools in the legs as a result. The heart compensates by racing. Clinicians associate this subtype with small fiber neuropathy and partial sympathetic denervation. This subtype responds well to therapies that improve peripheral vasoconstriction, which is why subtype identification changes everything about the treatment plan.
2. Hyperadrenergic Subtype
Excess norepinephrine drives the hyperadrenergic presentation. Standing triggers an abnormal adrenaline-related surge in the nervous system. This produces a rapid heart rate, elevated blood pressure, anxiety-like symptoms, tremor, and sometimes migraine headaches. A standing norepinephrine level of 600 pg/mL or higher is a commonly used, though not exclusive, diagnostic criterion for this subtype per Heart Rhythm Society/LAHRS guidance. Some patients meet the clinical picture without reaching this threshold, which is why the full neurological workup matters.
3. Hypovolemic Subtype
Up to 70 percent of POTS patients have reduced blood and plasma volume, according to Dysautonomia International. For a specific subset, this volume deficit is the primary driver. The heart races upon standing because the body lacks enough circulating volume to maintain venous return to the brain. Treatments targeting volume expansion directly address this mechanism.
A Note on Brainstem and Central Dysregulation
Brainstem and central autonomic dysregulation is an active and important area of research. The vestibular nuclei sit immediately adjacent to the nucleus tractus solitarius and the dorsal motor nucleus of the vagus, which are central hubs of cardiovascular regulation. Impaired brainstem circuits can affect both eye movement control and cardiovascular tone. Per the 2015 Heart Rhythm Society expert consensus and Raj et al. in CMAJ (2022), the three recognized primary subtypes are neuropathic, hyperadrenergic, and hypovolemic. Brainstem and central dysregulation does not hold a separate classification in either guideline. It is an active research topic and is highly relevant clinically for patients who have not responded to standard subtype-targeted care and who have never received a comprehensive neurological evaluation.
The Functional Neurology Approach at GCNC
A positive tilt table test confirms the diagnosis. It does not explain the cause. The brainstem circuits that regulate eye movement also regulate cardiovascular tone. When vestibular nuclei function is impaired, autonomic output suffers. Managing POTS as a purely cardiac condition misses this neurological layer entirely, and it is exactly the layer that functional neurology is equipped to assess.
Most cardiology and internal medicine settings do not have the specialized tools needed to evaluate these central nervous system patterns. Georgia Chiropractic Neurology Center uses a multi-modal evaluation suite that goes well beyond tilt table testing to find the specific neurological drivers for each patient.
- NeuroInfiniti is a multi-modal autonomic and stress response system. It simultaneously records heart rate variability (HRV), skin conductance, respiration, and electromyography. This identifies whether the patient is parasympathetic or sympathetically dominant and quantifies the autonomic reserve available for rehabilitation.
- HeartMath Inner Balance and emWave are used both in-session and as take-home tools for HRV biofeedback training. Patients actively shift their autonomic state under guided coaching.
- Polar H10 chest-strap ECG delivers clinical-grade RR-interval data during active orthostatic and rehabilitation testing.
- VNG and vHIT goggles test vestibulo-ocular reflex (VOR) function. The VOR sits at the intersection of vestibular and autonomic processing. Asymmetric responses are direct evidence that brainstem circuits regulating both eye movement and cardiovascular tone are not functioning properly.
- Computerized Dynamic Posturography uses the Clinical Test of Sensory Interaction and Balance (CTSIB) protocol to evaluate sensory integration and postural stability across multiple sensory conditions.
- Saccadometry assesses brainstem and frontal eye field function. Dysmetric saccades are direct evidence of brainstem circuit dysfunction.
- Pupillometry tracks the autonomic pupillary response continuously through examination and treatment.
A patient whose tilt table is positive but whose brainstem circuitry has never been examined has not received a complete autonomic workup. This is one of the most consistently overlooked patterns in patients who arrive after cardiology-only evaluations.
One case from the center shows the impact of subtype accuracy. A patient arrived with a clinical presentation suggesting hyperadrenergic POTS. Comprehensive autonomic monitoring revealed the actual subtype was neuropathic. Small nerves in the lower legs were not properly signaling blood vessels to constrict. Instead of medications targeting adrenaline suppression, the team used targeted peripheral nerve stimulation to improve the underlying signaling deficiency. The patient experienced relief that years of standard treatment had not produced.
Evidence-Based Treatment Strategies
Treatment guidelines from the 2015 Heart Rhythm Society consensus, the Canadian Cardiovascular Society, and the NIH Expert Consensus Meeting consistently recommend a combined clinical approach. No FDA-approved drug currently exists for POTS. Physicians prescribe all pharmacological treatments off-label. The MedlinePlus overview of POTS and the Cleveland Clinic POTS guide are helpful starting references for patients and families.
Non-Pharmacological Foundations
Non-pharmacological treatment is the first-line approach for every patient. It does not replace subtype-targeted care, but it builds the physiological foundation that all other therapies need.
Patients should consume two to three liters of water daily with eight to 10 grams of sodium. High sodium intake expands plasma volume and lowers standing heart rate. A 2021 randomized crossover trial by Garland et al. in JACC confirmed that a high-sodium diet significantly reduced orthostatic heart rate, corrected plasma volume deficits, and lowered standing norepinephrine in POTS patients compared with a low-sodium diet.
Full-body compression garments, especially abdominal compression, reduce venous pooling upon standing. A 2021 randomized controlled trial by Bourne et al. in JACC found that combining abdominal and leg compression significantly reduced orthostatic tachycardia and symptom burden. Abdominal compression alone outperforms leg compression alone.
Exercise is the only intervention that directly addresses cardiovascular deconditioning. Research by Fu and Levine shows that three to six months of structured, progressive exercise reduces orthostatic heart rate, increases stroke volume, and improves quality of life. Patients should begin in a semi-recumbent position using rowing machines, swimming, or recumbent bikes. Moving to upright exercise too quickly worsens symptoms and reduces adherence.
Heat, prolonged standing, large carbohydrate meals, alcohol, and caffeine all worsen symptoms. Physical countermoves such as leg crossing, muscle tensing, and forward bending increase venous return and can blunt acute symptom spikes.
Pharmacological Interventions
A 2025 systematic review by Schiweck et al. in Clinical Autonomic Research analyzed 45 clinical studies on pharmacological and non-pharmacological care in POTS. The three most studied medications were beta-blockers, ivabradine, and midodrine.
Ivabradine showed the highest symptomatic improvement rate, helping approximately 74 to 78 percent of treated patients. It reduces heart rate by blocking the If channel in the sinus node without affecting blood pressure or cardiac contractility. This makes it especially valuable for patients who cannot tolerate beta-blockers or who have low baseline blood pressure. A 2021 randomized controlled trial by Taub et al. confirmed that ivabradine significantly reduced heart rate and improved quality of life in POTS patients compared with placebo.
Midodrine showed symptomatic response rates of approximately 60 to 70 percent in recent analyses, with earlier studies citing higher figures. The drug is an alpha-1 agonist that promotes peripheral vasoconstriction. It works well in neuropathic and hypovolemic presentations where vasoconstriction is deficient. It is significantly less effective in hyperadrenergic presentations. A double-blind crossover study by Ross et al. in Clinical Science demonstrated that midodrine reduced orthostatic tachycardia in neuropathic patients but had little benefit in hyperadrenergic patients. This is a clear example of why subtype identification changes treatment outcomes.
Beta-blockers such as propranolol, metoprolol, and bisoprolol yielded approximately 64 percent symptomatic response rates. Low-dose propranolol (10 to 20 mg) is preferred. Higher doses often worsen fatigue. These medications have a narrower benefit profile outside of hyperadrenergic presentations, and clinical teams typically use them as part of a broader plan rather than as standalone therapy.
Pyridostigmine, an acetylcholinesterase inhibitor, modestly reduces tachycardia and may help with fatigue, muscular weakness, and gastrointestinal symptoms. Clinicians use it primarily when autonomic ganglionic activity is insufficient.
Fludrocortisone is a synthetic mineralocorticoid used for volume expansion. Evidence on its efficacy is mixed. At higher doses, it can worsen headaches, affect mood, and lower potassium levels. Clinical teams monitor patients closely when using it and do not rely on it as a sole first-line agent.
Emerging and Investigational Therapies
Non-invasive transcutaneous vagus nerve stimulation (tVNS) applied to the tragus of the ear is showing strong promise. A 2024 randomized clinical trial by Stavrakis et al., published in JACC Clinical Electrophysiology, found that dailytVNS significantly reduced orthostatic heart rate compared to sham stimulation over a two-month period. A 2025 study in post-COVID patients confirmed that low-level tragus stimulation improved HRV, reduced sympathetic dominance, and lowered neuropeptide Y levels, with benefits maintained at one-year follow-up. The tragus carries direct branches of the vagus nerve, so stimulating it enhances parasympathetic tone while reducing sympathetic overactivity.
A subset of POTS patients have identifiable autoimmune involvement, including antibodies targeting adrenergic, muscarinic, and ganglionic acetylcholine receptors. A 2025 review in Frontiers in Cellular and Infection Microbiology summarized case series showing clinical improvements with intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin, therapeutic plasma exchange, and low-dose naltrexone in refractory autoimmune cases. A small 2024 RCT testing IVIG by Vernino et al. showed a trend toward benefit but did not reach statistical significance, likely due to small sample size and lower dosing than is typical for autoimmune conditions. The NIH RECOVER-AUTONOMIC platform trial includes one dedicated arm evaluating IVIG against a saline placebo and a separate arm testing ivabradine against placebo. The trial completed enrollment in July 2025, and results will add significantly to the evidence base.
HRV biofeedback trains patients to shift their autonomic state through guided breathing and relaxation. Clinicians use it as a complementary intervention alongside standard care. It builds autonomic reserve and reduces symptom burden over time.
Patient-Centric Outcomes
Many patients arrive at specialized centers after years of appointments, multiple medication trials, and symptoms that standard care has not fully addressed. Finding real answers and lasting relief after that journey is both possible and happening for more patients every year.
Melissa L., a patient in Georgia, shared her experience directly: “I’m so grateful to have found GCNC! The worst of my issues when I came here was POTS and Vertigo. They have helped SO much with both of these things and have been an advocate for my care in other areas. I recommend any and everyone who is having problems to go see them.”
Dawn M. described what it meant to finally find a provider who identified the underlying issue after many previous attempts: “Dr. Ellis is phenomenal. I have been to dozens and dozens of doctors and practitioners of all different styles and Dr. Ellis truly stands out among the best! He was able to quickly assess what the underlying issue was and was able to restore balance to my body in a way that I have been searching for, for years. If you have tried ‘everything’ or want to save dozens of other visits, Doctor Ellis is a must!”
When to Seek Specialized Evaluation
Consider a specialized neurological autonomic evaluation if you have a confirmed diagnosis but have not responded to standard care. Generic protocols do not address the specific mechanism driving your symptoms. Advanced evaluation is especially important if you have tried salt loading, fluid increases, and baseline medications without adequate relief.
Seek specialized care if you experience significant brain fog, vestibular symptoms, or visual disturbances alongside your primary diagnosis. Post-COVID or post-concussion onset, related vertigo, balance problems, or chronic headache all point to a need for deeper neurological screening. Most importantly, if you have a general POTS diagnosis but no defined subtype, a comprehensive evaluation can change the entire direction of your care.
Georgia Chiropractic Neurology Center in Marietta, Georgia provides full neurological autonomic workups, vestibular and oculomotor assessments, HRV profiling, and subtype-targeted rehabilitation. Learn more or request an evaluation here.
Frequently Asked Questions
Which medication works best for neuropathic POTS?
The neuropathic subtype responds best to treatments that improve peripheral vasoconstriction. Midodrine, an alpha-1 agonist, promotes blood vessel constriction in the lower extremities. Clinical studies confirm it reduces orthostatic heart rate in neuropathic patients specifically, while showing little effect in hyperadrenergic patients.
Why do standard fluid and salt treatments fail for some patients?
Standard treatments work well for hypovolemic presentations but may not address the root cause in neuropathic or hyperadrenergic subtypes. Without subtype testing, there is no way to know which mechanism is driving symptoms. That is why a generic protocol succeeds for some and fails for others.
How does a functional neurology assessment differ from a cardiology workup?
A cardiology workup typically ends after the tilt table confirms an abnormal heart rate response. A functional neurology assessment adds vestibulo-ocular reflex testing, saccadometry, computerized dynamic posturography, and pupillometry to examine the brainstem circuits that regulate both eye movement and cardiovascular tone. This reveals patterns that tilt table testing alone cannot detect.
Can vagus nerve stimulation help with a racing heart rate?
Yes, the evidence is growing. A 2024 randomized clinical trial by Stavrakis et al. found that daily tVNS applied to the tragus significantly reduced orthostatic heart rate over two months compared to sham treatment. Larger trials are underway to confirm these findings across broader patient populations.
Is POTS treatable?
Yes. While POTS has historically been underrecognized, treatment outcomes have improved significantly as subtype-specific care has become more widely available. Most patients see meaningful improvement with the right combination of non-pharmacological foundations, targeted medications, and neurological rehabilitation. The key is matching the treatment to the subtype.
Data based on internal clinical outcome assessments and patient-reported symptom surveys. Individual results vary. GCNC does not manage or alter prescriptions. All medication changes are performed under the direction of the patient’s prescribing physician.